Brown & Brown forecasts Q4 EPS at $0.90 and $1.65B revenue; price targets trimmed to $83-$105
Brown & Brown will report fourth-quarter results on January 26 with analysts forecasting EPS of $0.90 versus $0.86 a year ago and revenues of $1.65 billion compared to $1.18 billion in Q4 2024. The company declared a 16.5-cent quarterly dividend, while analysts’ price targets were cut to $83-$105 and one set at $91.
1. Attractive Valuation for a Proven Compounder
Brown & Brown’s recent pullback offers an appealing entry point for long-term investors in a company that has demonstrated consistent profitability and capital allocation discipline. Management highlights a temporary soft patch in organic revenue—declining 2.8% in Q4 2025—driven by non-recurring adjustments and rate declines in certain catastrophe lines. These headwinds are expected to normalize, and the firm’s scale advantage should resume driving free cash flow (FCF) growth.
2. Robust Q4 2025 and Full-Year Financial Performance
In the quarter ended December 31, 2025, total revenues rose 35.7% year-over-year to $1.6 billion, boosted by the Accession acquisition, while adjusted EBITDAC reached $529 million (32.9% margin). Organic revenues were $1.08 billion. Net income attributable to shareholders increased 25.7% to $264 million, with adjusted diluted EPS of $0.93, up 8.1% from the prior year. For the full year, revenues climbed 22.8% to $5.9 billion, adjusted diluted EPS grew 10.9% to $4.26, and adjusted EBITDAC margin expanded to 35.9%.
3. Scale-Driven Free Cash Flow and Capital Allocation
Brown & Brown’s M&A pipeline remains robust, with the recent Accession deal contributing to both scale and cross-selling opportunities. Management estimates 2025 FCF per share at $2.08, reflecting strong conversion of adjusted EBITDAC to cash. The balance sheet supports continued bolt-on acquisitions: at year-end, total debt was $7.6 billion against $1.08 billion of cash, while retained earnings reached $6.99 billion. The firm’s disciplined approach to integration costs and earn-out adjustments underpins its double-digit free cash flow growth outlook.
4. Long-Term Outlook and Investor Implications
Looking ahead, management anticipates organic revenue growth to rebound as non-recurring impacts fade and catastrophe rate resets stabilize. Continued margin expansion is expected through operational leverage and low incremental acquisition costs. Given the compounder’s track record—over 20% cumulative revenue growth since 2020 and consistent EPS growth—investors evaluating Brown & Brown at today’s valuation can position for multi-year free cash flow appreciation and potential dividend increases.